Omega-3 carboxylic acid clinical trials
Also written Epanova.
How each study uses omega-3 carboxylic acid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 5 May 2014 · EPANOVA · NDA 205060 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses omega-3 carboxylic acid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With HypertriglyceridemiaCompletedPhase 3AstraZenecaNCT02104817Written as Epanova® (omega-3 carboxylic acids)How we know
- Epanova® for Lowering Very High Triglycerides II (EVOLVE II)CompletedPhase 3AstraZenecaNCT02009865Written as EpanovaHow we know
- A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.CompletedPhase 2AstraZenecaNCT02354976Written as Omega-3 carboxylic acidHow we know
- A Ph 1 Study of Epanova® in Healthy ChinesesCompletedPhase 1AstraZenecaNCT03574142Written as EpanovaHow we know
- A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic PatientsCompletedPhase 2AstraZenecaNCT02279407Written as Omega-3 carboxylic acidsHow we know
- A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEICompletedPhase 2AstraZenecaNCT02370537Written as Epanova® (omega-3 carboxylic acids)How we know
- Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)CompletedPhase 1AstraZenecaNCT02859129Written as Epanova™ QD (2 x 1 g capsules)How we know
- An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of PancreatitisCompletedPhase 1AstraZenecaNCT02189252Written as EpanovaHow we know
- [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROLCompletedPhase 3AstraZenecaNCT01408303Written as omega-3-carboxylic acids, 2gHow we know
- EPANOVA in Crohn's Disease, Study 1CompletedPhase 3Tillotts Pharma AGNCT00613197Written as EpanovaHow we know
- An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's DiseaseCompletedPhase 3Tillotts Pharma AGNCT00074542Written as Epanova™ (Omega-3 Free Fatty Acids)How we know
Given beside what is tested · 1 — omega-3 carboxylic acid is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with omega-3 carboxylic acid
Codes
What other systems call omega-3 carboxylic acid · ClinicalTrials.gg INT001349
- UNII (FDA) F85N2YHE4EOMEGA-3-CARBOXYLIC ACIDSOne source FDA
- RxNorm 1652071One source FDA
- NCI Thesaurus C170252Omega-3-carboxylic AcidsOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F85N2YHE4E | OMEGA-3-CARBOXYLIC ACIDS | One source FDA |
| RxNorm | 1652071 | — | One source FDA |
| NCI Thesaurus | C170252 | Omega-3-carboxylic Acids | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.